DHPA has submitted comments to the U.S. Health and Human Services Request for Information entitled “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.” In the comment letter, DHPA focuses on several of the key initiatives highlighted in the RFI: DHPA supports site neutrality for physician-administered drugs across the hospital and independent physician practice settings […]

DHPA joined with 215 advocacy groups to voice concern about Medicare Part B proposals outlined in President Trump’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs and corresponding Request for Information (RFI) that could have harmful consequences for patients with serious diseases. In a letter to HHS Secretary Alex Azar, the groups wrote, “As […]